Intravenous Stable Isotope Glycerol for Clinical Research

The National Institutes of Health, specifically the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), requires the procurement of intravenous stable isotope glycerol for use in human metabolic clinical studies. This requirement supports the NIDDK mission to conduct medical research into endocrine and metabolic diseases, nutritional disorders, and obesity. In accordance with the NIH Sterile Products for Human Administration Executive Committee and the NIH Office of Research Support and Compliance, the contractor is responsible for sourcing raw materials, manufacturing or packaging the isotope product, and releasing the final product to the NIH Clinical Center Pharmacy following all required microbial and analytical testing.

This pre-solicitation, identified by solicitation number 75N98026Q00598, is designated as an 8A; 8A set-aside. The primary classification for this requirement is NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6810 CHEMICALS. All work will be performed in Bethesda, MD, under the oversight of the National Institutes of Health OLAO. James B. Law serves as the point of contact for this notice.

The response deadline for this opportunity is June 11, 2026. The notice was published and last updated on June 11, 2026, and currently includes zero attachments. This procurement ensures that stable isotopes used by NIDDK principal investigators meet minimum requirements for safety and efficacy in clinical research settings.